PLK

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

PLK

PLK related products

Cat No.	Product Name	CAS No.	Product Description
V1573	BI 2536	755038-02-9	BI2536 (BI-2536; BI 2536) is a novel PLK1/BRD4 dual inhibitor with potential antitumor activity.
V52314	BTO-1	40647-02-7	BTO-1 is a Polo-like kinase (Plk) inhibitor.
V2729	Ocifisertib (CFI-400945)	1338806-73-7	CFI400945 is a potent, selective, and orally bioavailable PLK4 (polo-like kinase 4) inhibitor with IC50 value of 2.8 ±1.4 nM and potential antineoplastic activity.
V1576	GSK461364	929095-18-1	GSK-461364 (GSK461364; GSK 461364)is a novel, potent, selective, reversible and ATP-competitive small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antitumor activity.
V1577	HMN-214	173529-46-9	HMN-214 (HMN 214; HMN214), stilbene derivative, is a potent and orally bioactive prodrug of HMN-176, which alters the cellular spatial orientation of Plk1 (polo-like kinase-1).
V1578	MLN0905	1228960-69-7	MLN0905 (MLN-0905; MLN 0905) is a novel, potent and selective small-molecule inhibitor of polo-like kinase-1 (PLK1) with potential antineoplastic activity.
V88743	PLK1-IN-10	2991469-21-5	PLK1-IN-10 (Compound 4Bb) is an orally available PLK1 PBD (polo-box domain) inhibitor.
V88746	PLK1-IN-9	893772-67-3	PLK1-IN-9 (Compound M2) is a polo-like kinase 1 (PLK1) inhibitor that inhibits PLK protein modified by peptide 1010pT, cdc25c, and PBIP with IC50 of 1.6, 0.8, and 1.4 μM, respectively.
V1580	NMS-P937 (NMS1286937; Onvansertib)	1034616-18-6	NMS-P937 (also know as NMS-P937;NMS1286937;NMS-P-937; NMS-P 937; Onvansertib) is an orally bioavailable, potent, selective, small-molecule Polo-like Kinase 1 (PLK1) inhibitor with potential antitumor activity.
V84180	PLK4-IN-4	2923999-01-1
V115581	PLK4-IN-6		PLK4-IN-6 (compound C05) is a PLK4 inhibitor (IC50 < 0.1 nM).
V110858	PLK4-IN-7		PLK4-IN-7 is a highly selective, orally effective PLK4 inhibitor with an IC50 value of 7.9 nM.
V109335	POI ligand-3		POI ligand-3 (compound 4j) is a peptide PLK1 PBD inhibitor.
V1579	Ro3280 (Ro5203280)	1062243-51-9	RO3280 (also known as Ro-5203280; RO 3280; Ro5203280; RO-3280) is a novel, potent and highly selective inhibitor of Polo-like kinase 1 (PLK1) with potential anticancer activity.
V144376	RP-1664	2980682-00-4	RP-1664 is a highly selective, orally effective PLK4 inhibitor with an IC50 value of 3 nM.
V1581	SBE 13 HCl	1052532-15-6	SBE 13 HCl (SBE13; SBE-13), the hydrochloride salt of SBE13, is a novel, potent and selective Polo-like Kinase 1 (PLK1) inhibitor with potential antineoplastic activity.
V104023	TTK/PLK1-IN-1	1817791-70-0	TTK/PLK1-IN-1 (Formula I) is an inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC50 of 7 nM and 72 nM, respectively.
V1574	Volasertib (BI 6727)	755038-65-4	Volasertib (formerly also known as BI6727, BI-6727, BI 6727) is a novel and highly potent dihydropteridinone-based Plk1 (polo-like kinase 1) inhibitor with potential antineoplastic activity.